{"groups":[{"description":"First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 40 mg daily after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"FG000","title":"First-line Afatinib 40 mg"},{"description":"First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"FG001","title":"First-line Afatinib 50 mg"},{"description":"Second-line patients received a starting oral dose of Afatinib 40 mg daily only after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"FG002","title":"Second-line Afatinib 40 mg"},{"description":"Second-line patients received a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"FG003","title":"Second-line Afatinib 50 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"8"}],"type":"Other Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"49"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Refused continuation of study medication"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}],"type":"Other than stated"}],"milestones":[{"achievements":[{"comment":"entered and treated","groupId":"FG000","numSubjects":"23"},{"comment":"entered and treated","groupId":"FG001","numSubjects":"38"},{"comment":"entered and treated","groupId":"FG002","numSubjects":"7"},{"comment":"entered and treated","groupId":"FG003","numSubjects":"61"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"61"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}